164 related articles for article (PubMed ID: 12114110)
1. Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders.
Kipnis J; Schwartz M
Trends Mol Med; 2002 Jul; 8(7):319-23. PubMed ID: 12114110
[TBL] [Abstract][Full Text] [Related]
2. Specific vaccines against autoimmune diseases.
Sela M
C R Acad Sci III; 1999 Nov; 322(11):933-8. PubMed ID: 10646086
[TBL] [Abstract][Full Text] [Related]
3. Protective autoimmunity and neuroprotection in inflammatory and noninflammatory neurodegenerative diseases.
Schwartz M; Kipnis J
J Neurol Sci; 2005 Jun; 233(1-2):163-6. PubMed ID: 15949502
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic T cell-based vaccination for neurodegenerative disorders: the role of CD4+CD25+ regulatory T cells.
Schwartz M; Kipnis J
Ann N Y Acad Sci; 2005 Jun; 1051():701-8. PubMed ID: 16127010
[TBL] [Abstract][Full Text] [Related]
5. Neurogenesis and neuroprotection in the CNS--fundamental elements in the effect of Glatiramer acetate on treatment of autoimmune neurological disorders.
Arnon R; Aharoni R
Mol Neurobiol; 2007 Dec; 36(3):245-53. PubMed ID: 17955199
[TBL] [Abstract][Full Text] [Related]
6. Multiple sclerosis as a by-product of the failure to sustain protective autoimmunity: a paradigm shift.
Schwartz M; Kipnis J
Neuroscientist; 2002 Oct; 8(5):405-13. PubMed ID: 12374425
[TBL] [Abstract][Full Text] [Related]
7. Application of glatiramer acetate to neurodegenerative diseases beyond multiple sclerosis: the need for disease-specific approaches.
Schwartz M; Bukshpan S; Kunis G
BioDrugs; 2008; 22(5):293-9. PubMed ID: 18778111
[TBL] [Abstract][Full Text] [Related]
8. Harnessing the immune system for neuroprotection: therapeutic vaccines for acute and chronic neurodegenerative disorders.
Schwartz M
Cell Mol Neurobiol; 2001 Dec; 21(6):617-27. PubMed ID: 12043837
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis.
Angelov DN; Waibel S; Guntinas-Lichius O; Lenzen M; Neiss WF; Tomov TL; Yoles E; Kipnis J; Schori H; Reuter A; Ludolph A; Schwartz M
Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4790-5. PubMed ID: 12668759
[TBL] [Abstract][Full Text] [Related]
10. B cells in autoimmune and neurodegenerative central nervous system diseases.
Sabatino JJ; Pröbstel AK; Zamvil SS
Nat Rev Neurosci; 2019 Dec; 20(12):728-745. PubMed ID: 31712781
[TBL] [Abstract][Full Text] [Related]
11. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
Wolinsky JS; Narayana PA; Johnson KP;
Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192
[TBL] [Abstract][Full Text] [Related]
12. Glatiramer acetate in the treatment of multiple sclerosis.
Sela M; Teitelbaum D
Expert Opin Pharmacother; 2001 Jul; 2(7):1149-65. PubMed ID: 11583066
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.
Dhib-Jalbut S
Neurology; 2002 Apr; 58(8 Suppl 4):S3-9. PubMed ID: 11971121
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory vaccines against autoimmune diseases.
Sela M
Rejuvenation Res; 2006; 9(1):126-33. PubMed ID: 16608409
[TBL] [Abstract][Full Text] [Related]
15. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease.
Ben-Nun A; Mendel I; Bakimer R; Fridkis-Hareli M; Teitelbaum D; Arnon R; Sela M; Kerlero de Rosbo N
J Neurol; 1996 Apr; 243(4 Suppl 1):S14-22. PubMed ID: 8965116
[TBL] [Abstract][Full Text] [Related]
16. The concept of specific immune treatment against autoimmune diseases.
Sela M
Int Rev Immunol; 1999; 18(3):201-16. PubMed ID: 10614724
[TBL] [Abstract][Full Text] [Related]
17. Copolymer 1 inhibits manifestations of graft rejection.
Aharoni R; Teitelbaum D; Arnon R; Sela M
Transplantation; 2001 Aug; 72(4):598-605. PubMed ID: 11544417
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.
Aharoni R
J Autoimmun; 2014 Nov; 54():81-92. PubMed ID: 24934599
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulation induced by central nervous system-related peptides as a therapeutic strategy for neurodegenerative disorders.
Palumbo ML; Moroni AD; Quiroga S; Castro MM; Burgueño AL; Genaro AM
Pharmacol Res Perspect; 2021 Oct; 9(5):e00795. PubMed ID: 34609083
[TBL] [Abstract][Full Text] [Related]
20. Limited effects of glatiramer acetate in the high-copy number hSOD1-G93A mouse model of ALS.
Habisch HJ; Schwalenstöcker B; Danzeisen R; Neuhaus O; Hartung HP; Ludolph A
Exp Neurol; 2007 Aug; 206(2):288-95. PubMed ID: 17597611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
